Asier Unciti-Broceta
Innovative Therapeutics
Research in a Nutshell
The Innovative Therapeutics Lab is led by Professor Asier Unciti-Broceta and based at Edinburgh Cancer Research, part of the Institute of Genetics and Cancer at the University of Edinburgh, where Asier established the first chemistry lab of the Institute in 2010. The lab explores novel chemical strategies to improve the efficacy and safety of cancer treatments. This includes development of highly-selective inhibitors of kinases involved in cancer and novel prodrug strategies aimed at improving the clinical use of well-established chemotherapy drugs.
People |
|
Professor of Medicinal Chemistry and Head of the Innovative Therapeutics Lab |
|
Catherine Adam | Chemistry Lab Manager |
Alvaro Lorente-Macías | Lead Synthetic Chemist |
Yang Ge | EPSRC Postdoctoral Fellow |
Athina Polykandritou | MRC Postdoctoral Fellow |
Davir González | EPSRC Postdoctoral Fellow |
Bobby Kaghazchi | Nuvectis Postdoctoral Fellow |
Ben King | PhD student |
Iñigo Lanzagorta Calvillo | PhD student |
Jonathon Mock | PhD student |
Ross Milnes | PhD student |
Adam Smith | PhD student |
Ben Jones | Visiting PhD student |
John Hajek | 5th year MChem student |
Contact
Collaborations
-
Professor Neil Carragher (ECRC)
-
Dr Liz Patton (ECRC)
- Professor Val Brunton (ECRC)
- Professor Margaret Frame (ECRC)
- Professor H. Leung (Beatson Institute / University of Glasgow)
- Dr P. Brennan (Centre for Clinical Brain Sciences / University of Edinburgh)
- Dr D. Sieger (Centre for Neuroregeneration / University of Edinburgh)
- Dr C. Torres-Sánchez (Loughborough University)
- Dr R. Sanchez-Martín and Dr J. J. Díaz-Mochón (GENyO / Spain)
- Professor I. Molina (University of Granada / Spain)
Scientific Themes
Anticancer Therapy, Kinase Inhibitors, Bioorthogonal Prodrugs, Palladium Implants, Nanotechnology
Technology Expertise
Small Molecule Synthesis and Peptides, Medicinal Chemistry, Design and Development of Prodrugs, Target ID and Imaging Tools, Heterogeneous Catalysts